MKI67 and craniopharyngioma: Recent studies have discovered that Ki67 can be used as a diagnostic and prognostic biomarker in renal cancer (6), breast cancer (20, 22), ovarian cancer (23), craniopharyngioma (24) and neuroendocrine neoplasms (25).